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Ebola virus can persist in semen after recovery, poten-
tially for months, which may impact the duration of 
enhanced surveillance required after interruption of 
transmission. We combined recent data on viral RNA 
persistence with weekly disease incidence to estimate 
the current number of semen-positive men in affected 
West African countries. We find the number is low, and 
since few reported sexual transmission events have 
occurred, the future risk is also likely low, although 
sexual health promotion remains critical.
In this study, a negative binomial distribution is fitted 
to recent data on persistence of Ebola virus (EBOV) 
RNA in semen after Ebola virus disease (EVD) symptom 
onset in EVD survivors. Given the prior reported inci-
dence of EVD in each affected region of Guinea, Liberia, 
and Sierra Leone, the fitted distribution is used to esti-
mate and model the number of men in these countries 
with EBOV RNA present in semen, in each week since 
mid-2014. According to this, the total number of EBOV 
RNA semen-positive individuals in January 2016 would 
be low (n=73; 95% confidence interval (CI): 15–331). 
Since few reported sexual transmission events have 
been documented [1], the future risk of such transmis-
sion is also likely low.
Modelling Ebola virus RNA persistence in 
semen 
EBOV can persist in immunoprivileged sites within 
the body after recovery from infection, specifically in 
semen [1,2]. Post-recovery sexual transmission (PRST) 
of EBOV via semen has been documented in the ongo-
ing West African outbreak [3]. Understanding potential 
EBOV shedding after recovery is critical to determining 
duration of surveillance of survivors, and may impact 
the length of enhanced surveillance following the inter-
ruption of transmission in a country; which currently 
begins 42 days after the final case and lasts 90 days 
[4]. Sierra Leone is currently the only country in West 
Africa in the enhanced surveillance period, which 
began on 7 November 2015. 
In a separate study, ninety three men had one semen 
test two to 10 months after onset of confirmed EVD 
symptoms [1]. Samples were tested by reverse tran-
scription-polymerase chain reaction (RT-PCR) for 
the presence of EBOV RNA. A positive test by RT-PCR 
means that viral RNA is present, but does not neces-
sarily mean that infectious virus is present in the sam-
ple. The number of positive, negative, or indeterminate 
samples was reported by month since onset of EVD 
symptoms and we took the number of days to be the 
mid-point of each month (Table 1).
We estimated the probability that semen was no longer 
RNA positive by the sampling time, where indetermi-
nate samples were treated as negative. We fitted a 
negative binomial distribution for the semen clearance 
time, by maximum likelihood (Figure 1). We extrapolate 
to 85 weeks after symptom onset. 
Estimating numbers of men with Ebola 
virus RNA in semen in West Africa
The fitted distribution was used to calculate the num-
ber of men with semen positive for EBOV RNA present 
each week, given the prior incidence of EVD in each 
affected region of Guinea, Liberia, and Sierra Leone.
For each area (prefecture, county or district) in Guinea, 
Liberia and Sierra Leone, we use confirmed and proba-
ble cases available from the World Health Organization 
(WHO). The WHO patient database, which is curated 
and more accurate than the situation reports but sub-
ject to delay, was used except for recent weeks where 
we switch to the WHO situation reports (1 January 2014 
to 11 October 2015) because counts were more up to 
date [5]. Except for the Western Area Districts, Sierra 
Leone (switch date: 3 May 2015; data not shown), the 
switch date between WHO data sources was defined 
within the six weeks prior to the publication date of the 
last week reported (14 October 2015), as the earliest 
week when the number of cases in the situation report 
exceeded that in the WHO patient database. 
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We assume 60% case fatality for all weeks, and that 
40% of survivors are male adults [6].
As of 8 November 2015, we estimate that the number 
of men who may have EBOV RNA-positive semen is 50 
(95% CI: 22–112), 15 (95% CI: 1–84) and 97 (95% CI: 
24–295) in Guinea, Liberia and Sierra Leone respec-
tively (Figure 2A). The geographical distribution is 
heterogeneous (Figure 2B) where the region with high-
est estimated numbers is the Western Area Urban 
District, Sierra Leone, at 33 (95% CI: 8–87). According 
to our analysis, in the first week of January 2015, the 
estimated total number of EBOV RNA semen-positive 
individuals was 2,255 (95% CI: 1,946–2,495), in week 
ending 8 November 2015 was 162 (95% CI: 47–491), and 
in January 2016 will be 73 (95% CI: 15–331). Therefore 
the bulk of person-weeks of risk have passed (Figure 
2A), although the infectiousness of EBOV-positive 
semen over time is not known.
Sensitivity analyses
Sensitivity of model of RNA persistence in 
semen to chosen distribution
Due to the low number of samples, and the lack of sam-
ples at long time periods, we are unable to determine 
which parametric distribution fits best (Figure 3). 
Results above are presented for the negative binomial 
distribution, and here we examine the sensitivity of our 
estimates to the chosen distribution. We show the fit 
to the data (Figure 3A), probability distribution of dura-
tion of semen RNA positivity (Figure 3B), and the num-
ber of EBOV RNA semen-positive individuals in the first 
week of January 2015, the week ending 8 November 
2015 and the first week of January 2016 for Guinea 
(Table 2), Liberia (Table 3) and Sierra Leone (Table 4). 
In all tested distributions the values for the number of 
individuals in January 2015 are comparable, as are esti-
mates on 8 November 2015. In estimates for January 
2016, the effect of the difference in the tail of the dis-
tributions becomes clearer.
Sensitivity to underreporting of estimations of 
numbers of men with Ebola virus RNA-positive 
semen
We tested the sensitivity of our estimates to the 
assumed fraction of EVD cases that are reported. We 
show estimates for complete (or 100% reporting) (as 
above), constant 70% reporting, or a rising reporting 
fraction, beginning at 30% early in of the epidemic 
(1 January 2014), reaching 95% near the end of the 
Figure 1
Fit of a negative binomial distribution to published data on detection of Ebola virus RNA in semen samples
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EBOV: Ebola virus.
A. Maximum likelihood (dark blue), 95% bootstrap interval (shaded) for the fitted distribution from 5,000 bootstrap samples. The negative 
binomial distribution has parameters size = 4.73 and probability = 0.16. Data are shown in black, with a 95% binomial confidence interval.
B. Maximum likelihood estimate (dark blue) and 95% bootstrap interval (shaded) of the duration of Ebola virus RNA semen positivity post 
Ebola virus disease onset.
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epidemic (11 October 2015) (Figure 4). Table 5 shows 
the estimated number in week ending 8 November 
2015, which is marked in Figure 4 as a grey line.
Although there are differences between the curves, 
by November 2015, the vast majority of surviving men 
would no longer be EBOV RNA semen-positive. Indeed, 
the number of men remaining is fairly small irrespec-
tive of underreporting.
Month Days Number Tested Positive Negative Indeterminate 
1 15 0 0 0 0
2 45 6 6 0 0
3 75 3 3 0 0
4 105 11 8 3 0
5 135 13 9 1 3
6 165 16 9 6 1
7 195 18 3 12 3
8 225 17 5 10 2
9 255 8 3 4 1
10 285 1 0 0 1
Table 1
Number of initial samples tested and time since Ebola 
virus disease onset
93 samples tested and reported in Deen et al. 2015 [1]. We use the 
midpoint of the month of testing as number of days.
Distribution
03 Jan 2015 08 Nov 2015 04 Jan 2016
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Negative binomial 345 (298–382) 50 (22–112) 24 (8–75)
Gamma 349 (304–386) 53 (24–114) 26 (9–77)
Weibull 344 (298–381) 47 (21–115) 22 (7–76)
Logistic 337 (281–379) 45 (22–94) 20 (8–56)
Normal 339 (283–381) 41 (21–89) 17 (7–49)
Lognormal 352 (309–387) 63 (26–131) 36 (10–96)
Table 2
Comparison of predicted number of Ebola virus RNA 
semen-positive survivors in Guinea on three dates 
according to the fitted distribution selected
CI: confidence interval.
Mean, lower and upper 95% CIs from 5,000 bootstrap samples are 
given.
Distribution
03 Jan 2015 08 Nov 2015 04 Jan 2016
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Negative binomial 567 (471–657) 15 (1–84) 6 (0–56)
Gamma 577 (481–668) 17 (2–86) 7 (1–58)
Weibull 570 (475–657) 9 (1–85) 3 (0–55)
Logistic 573 (473–663) 9 (2–52) 3 (1–28)
Normal 575 (475–664) 4 (1–40) 1 (0–17)
Lognormal 577 (481–671) 32 (3–116) 19 (1–90)
Table 3
Comparison of predicted number of Ebola virus RNA 
semen-positive survivors in Liberia on three dates 
according to the fitted distribution selected
CI: confidence interval.
Mean, lower and upper 95% CIs from 5,000 bootstrap samples are 
given.
Figure 2
Estimated numbers of men with semen positive for Ebola 
virus RNA, in Guinea, Liberia, and Sierra Leone (June 
2014–May 2016)
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Figure 3
Comparison of distributions that can be used to fit the available data on proportions of Ebola virus survivors with semen 
positive for Ebola virus RNA
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A. Maximum likelihood fit of each distribution is shown with the data (black circles).
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Figure 4
Effect of underreporting of true Ebola virus disease cases on the number of men with semen positive for Ebola virus RNA 
in Guinea, Liberia and Sierra Leone
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Maximum likelihood estimates and 95% confidence interval (CI) for the number of EBOV RNA positive men in Guinea (A), Liberia (B), and Sierra 
Leone (C). Complete (100%) reporting (blue), constant 70% reporting rate (green), and a monotonically rising reporting fraction, from 30% 
on 1 January 2014, to 95% by 11 October 2015 (orange).
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The maximum duration of EBOV RNA semen positivity 
is currently unknown, and in our analysis the inferred 
maximum duration is sensitive to the shape of the 
decay distribution chosen to fit the available data. 
The mean number of EBOV RNA semen-positive men at 
each time point is less sensitive to the choice of distri-
bution, although the confidence intervals vary widely 
on this assumption. 
Discussion
Our analysis indicates that the number of men remain-
ing in West Africa with EBOV RNA detectable in their 
semen is currently low and continuing to fall. The geo-
graphical distribution of these individuals is heteroge-
neous, and is related to past incidence levels and the 
timing of cases in those districts. 
To better understand the risk of onward transmission, 
the relationship between testing positive for EBOV 
RNA by RT-PCR, and the likelihood of sexual transmis-
sion needs quantification. Recent sexual transmission 
events [3] further highlight the urgent need for compre-
hensive survivor screening programmes, which include 
testing of bodily fluids such as semen to determine a 
more certain time at which RNA is no longer present. 
Such programmes would not only provide insight into 
how to protect the intimate contacts of survivors, but 
can provide reassurance to the many survivors who are 
likely no longer EBOV semen-positive.
Our base-case estimates do not include suspected 
cases, underreporting of symptomatic cases or the 
possibility of EBOV RNA-positive semen in asympto-
matic cases. Under these circumstances, the number 
of EBOV RNA semen-positive individuals is slightly 
increased (Figure 4). In addition, although we present 
point estimates for numbers of remaining EBOV RNA 
semen-positive survivors, the values rely not only on 
accurate EVD incidence data, but also on assumptions 
of constant survival rates, as well as statistical uncer-
tainty in the fitting procedure. Therefore, point esti-
mates should be interpreted with care, and attention 
given to the wide confidence intervals.
Up to 20 suspected PRST events have been reported 
in West Africa to date [1], although ring vaccination of 
at-risk contacts in Guinea may have reduced late trans-
mission [7]. Even assuming 20 PRST events to be a sub-
stantial underestimate, future numbers may be low. 
Given this low potential for transmission, we should be 
cautious not to further stigmatise an already marginal-
ised group. However, since a single PRST event could 
restart wider transmission, and the duration for which 
men may remain EBOV semen-positive is long, contin-
ued promotion of sexual health and EVD surveillance 
remain vital.
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Distribution
03 Jan 2015 08 Nov 2015 04 Jan 2016
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Negative binomial 1,343 (1,177–1,456) 97 (24–295) 43 (7–200)
Gamma 1,360 (1,201–1,469) 105 (27–302) 49 (8–205)
Weibull 1,337 (1,178–1,449) 83 (20–303) 31 (6–202)
Logistic 1,308 (1,109–1,446) 75 (23–227) 30 (7–129)
Normal 1,319 (1,114–1,453) 60 (19–207) 19 (6–104)
Lognormal 1,370 (1,224–1,473) 143 (36–360) 82 (13–273)
Table 4
Comparison of predicted numbers of Ebola virus RNA 
semen-positive survivors in Sierra Leone on three dates 
according to the fitted distribution selected
CI: confidence interval.
Mean, lower and upper 95% CI from 5,000 bootstrap samples are 
given.
Country Completeness of reporting Maximum likelihood (95% CI)
Guinea
Complete 50 (21–113)
Constant 70% 71 (30–162)
Rising 68 (27–168)
Liberia
Complete 15 (1–85)
Constant 70% 22 (2–121)
Rising 28 (2–163)
Sierra Leone
Complete 97 (22–300)
Constant 70% 139 (31–428)
Rising 163 (31–549)
Table 5
Estimated number of men with Ebola virus positive semen 
in Guinea, Liberia and Sierra Leone, as of 8 November 
2015 stratified by the value of underreporting assumed in 
the data
CI: confidence interval.
Maximum likelihood estimates, and 95% bootstrap CIs are given 
for complete case identification (100% reporting), constant 70% 
reporting, or a rising reporting fraction, beginning at 30% early 
in the epidemic (1 January 2014), reaching 95% by 11 October 
2015.
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